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1176Efficacy and Safety of Ciprofloxacin for Prophylaxis
of Polyomavirus BK Virus–Associated Hemorrhagic
Cystitis in Allogeneic Hematopoietic Stem Cell
Transplantation Recipients
Ashley N. Miller,1 Ashley Glode,2 Kathy R. Hogan,2 Christine Schaub,1
Cindy Kramer,3 Robert K. Stuart,1 Luciano J. Costa1Polyoma virus BK–induced hemorrhagic cystitis is an important cause of morbidity after hematopoietic stem
cell transplantation (HSCT). Fluoroquinolones have been shown in vitro to inhibit BK viral replication by
direct inhibition of the BK-encoded DNA gyrase. We hypothesized that extended prophylaxis with
ciprofloxacin may decrease the incidence of severe (grades 3 and 4) BK virus–associated hemorrhagic cystitis
(sBKHC) after HSCT. We retrospectively collected patient and transplant data, as well as incidence of
sBKHC, for all consecutive patients undergoing allogeneic HSCT between June 2006 and August 2010 at
our institution. Prophylaxis for sBKHC with ciprofloxacin 500 mg orally twice daily from day 0 until day
60 had been instituted in March 2009, delimiting a group receiving ciprofloxacin prophylaxis (CP) or no
prophylaxis (NP).We compared the cumulative incidence of sBKHC in CP andNP, including death in absence
of sBKHC as a competing risk. Ninety-two consecutive patients were included in the analysis, 44 in CP and 48
in NP. Median age of patients was 50 years (range: 19-70), and 47% received a myeloablative conditioning
regimen. The cumulative incidence of sBKHC was significantly reduced in CP (2.6% versus 20.9%,
P 5 .01). Multivariate Cox regression analysis revealed that assignment to CP and concomitant acute
graft-versus-host disease (GVHD) were the only factors independently associated with the occurrence of
sBKHC. Patients in CP did not experience a higher risk of Clostridium difficile diarrhea and were less likely
to develop episodes of bacteremia. Ciprofloxacin prophylaxis appears safe and effective in reducing the
incidence of severe BKHC after allogeneic HSCT.
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BK virus-associated hemorrhagic cystitis (BKHC)
is a potentially serious complication that occurs in
12% to 40% [1-7] of allogeneic hematopoietic stem
cell transplantation (HSCT) recipients. Clinical
manifestations of BKHC can be minor, with asympto-
matic hematuria, but can be severe, causing massive1Department of Medicine, Medical University of South
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even death [2,6,7].
Polyomavirus hominis 1, the BK virus, is present in
the urinary tract of .80% of adults and not linked
to any significant morbidity in immunocompetent
individuals [8,9]. In allogeneic HSCT patients, the
chemotherapy and irradiation from the conditioning
regimen cause damage to the urothelium cooperating
with the iatrogenic immunosupresive state to trigger
viral replication and shedding, alloimmune attack to
the urothelium, and finally bleeding [6,10-12].
Even thoughBKHCoccurs typically beyond 30 days
after transplantation [1,2,7,13], most of the events
implicated occur early, during an asymptomatic phase.
Indeed, the level of asymptomatic urinary shedding of
BK virus during the first 2 to 3 weeks after HSCT is
linked to the likelihood of development of symptomatic
BKHC at a latter time [6,14].
Most cases of BKHC are mild and self-limited, but
there are no treatments proven to be effective in de-
creasing the morbidity or the duration of severe
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tion and viral shedding occurring in the asymptomatic
phase of the disease provides opportunity to establish
an effective prophylactic intervention.
The antibacterial fluoroquinolone ciprofloxacin
carries inhibitory activity against the prokaryotic DNA
gyrase subunit A, can prevent BK virus replication in vi-
tro, and decrease the magnitude of BK virus shedding
following HSCT [14-16]. Because of preliminary
evidence that prolonged use of fluoroquinolones can
prevent episodes of severe BKHC [14], we instituted
universal prophylaxis with ciprofloxacin until day 60
after allogeneic HSCT. This report compares the inci-
dence of severe BKHC with and without prophylaxis
and provides confirmation of the safety and efficacy of
ciprofloxacin prevention for BKHC after allogeneic
HSCT.METHODS
Study Design
Prior to March 2009, all adult patients undergoing
allogeneic HSCT at the Medical University of South
Carolina (MUSC) received prophylaxis for opportu-
nistic bacterial infections from the day of transplanta-
tion until neutrophil engraftment (typically, the third
consecutive day of neutrophils .500/mm3) consisting
of ciprofloxacin 500 mg orally every 12 hours. In the
event of the patient developing fever and neutropenia,
ciprofloxacin was discontinued upon initiation of
broader spectrum parenteral antimicrobial coverage.
Motivated by preliminary evidence in the literature
of the impact of fluoroquinolones in preventing
BKHC, we changed our practice in March 2009 to in-
stitute prophylaxis with ciprofloxacin from day 0 until
day 60 after transplantation in all allograft recipients
(except patients allergic to ciprofloxacin). Patients
unable to take oral medication received the equivalent
dose of ciprofloxacin intravenously. We subsequently
obtained approval from the MUSC institutional
review board to retrospectively collect patient- and
transplant-related data and perform the present analy-
sis. All consecutive patients undergoing allogeneic
HSCT at MUSC between January 2006 and August
2010 are included in the analysis.
Definitions
BKHC was defined as the presence of hematuria,
concomitant urinary excretion of BK virus (as detected
by real-time polymerase chain reaction (PCR) for
a 72-nucleotide sequence from the VP-1 gene, with
a limit of detection of 10,000 copies/mL), and absence
of any other known cause for hematuria. Episodes
of BKHC were graded as follows: grade 1, microscopic
hematuria; grade 2, macroscopic hematuria; grade 3,
macroscopic hematuria with small blood clots;grade 4, massive macroscopic hematuria requiring
instrumentation of the urinary tract or causing urinary
retention [12]. Most episodes of grades 1 and 2 hemor-
rhagic cystitis are self-limited and associated with
minimal morbidity. Therefore, we only utilized the
occurrence of grades 3 and 4BKHC,hereafter called se-
vere BKHC, as an endpoint for the study.
With the intent to assess other disease and patient
characteristics associated with BKHC, we extracted
demographic data along with conditioning regimen,
type of donor, that is, sibling HLA matched donor or
alternative donor (matched andmismatched unrelated,
cord blood, or partially matched related donors), and
occurrence of clinically significant acute graft-versus-
host disease (aGVHD). Conditioning regimens were
defined as fully myeloablative if containing melphalan
$140 mg/m2 and/or total-body irridiation (TBI)
.500 cGy (single fraction) or 800 cGY (multiple frac-
tions) and/or busulfan .8 mg/kg (oral or intravenous
equivalent) [17]. All remaining conditioning regimens
were categorized as reduced intensity (RIC). The inci-
dence and severity of aGVHD had been prospectively
recorded according to IBMTR standards [18].Statistics
The main endpoint of the study was to compare
the cumulative incidence of severe BKHC between
the group of patients receiving prophylaxis with cipro-
floxacin (PC) and the group not receiving prophylaxis
(NP). For this comparison, we utilized competing risk
analysis with development of severe BKHC and death
in absence of severe BKHC as competing events.
Because several factors influence the incidence of
severe BKHC [3,7], and to account for the possible
disproportionate frequency of these factors in PC and
NP, we performed a multivariate analysis for the
endpoint of cumulative incidence of severe BKHC
employing Cox proportional hazard regression analysis.
This analysis included use of ciprofloxacin prophylaxis,
intensity of conditioning regimen (myeloablative versus
RIC), donor type (sibling matched versus alternative
donor), age of the patient, occurrence of grades B-D
GVHD, and the use of a uroprotective agent during
conditioning (mesna) as covariables. Variables to be
included in the final model were selected utilizing the
forward stepwise method.
Extended use of antibacterial drugs can lead to the
development of Clostridium difficile diarrhea in HSCT
patients and emergence of infections caused by antibi-
otic-resistant bacteria [19,20]. Therefore, we
compared the incidence of bacteremia and C. difficile
diarrhea during the 100 days after transplantation in
PC and NP. Because the groups had dissimilar
duration of follow-up, incidence of bacteremia and
C. difficile diarrhea were normalized and presented as
episodes/100 days at risk. All comparisons between
1178 Biol Blood Marrow Transplant 17:1176-1181, 2011A. N. Miller et al.rates utilized Fisher’s exact test. All inferential analyses
were done for a\ 0.05.RESULTS
Patient Characteristics
Ninety-two consecutive patients were included in
the analysis, of which 44 received ciprofloxacin pro-
phylaxis. Median age of patients was 50 years (range:
19-70), and 38% were female. All living patients had
at least 30 days of follow-up. Median follow-up for
patients in the ciprofloxacin and control groups were,
respectively, 175 (range: 16-549) and 515 days (range:
29-1706). Characteristics of patients included in both
groups are displayed in Table 1. Patients in the PC
group were, in general older, more likely to receive
a transplant from an alternative (non-HLA matched
sibling) donor, and less likely to receive amyeloablative
regimen than patients in the NP group. Only 1 patient
in the entire study received a conditioning regimen
containing thymoglobulin, a known risk factor for
BKHC [21].Incidence of Severe BKHC
Among the 48 patients in the NP group, 4 never
received ciprofloxacin because of allergy. Of the re-Table 1. Characteristics of the Patients
NP PC
Pn 5 48 n 5 44
Age* 44 (31-56) 55 (44-62) .001
Sex (female) 20 (42%) 15 (34%) .455
Diagnosis
AML 18 (37%) 19 (43%)
MDS 9 (19%) 5 (11%)
ALL 7 (15%) 3 (7%)
NHL 6 (13%) 7 (16%)
CLL 1 (2%) 2 (5%)
Other 2 (4%) 7 (16%)
CML 5 (10%) 1 (2%)
Donor
HLA matched sibling 24 (50%) 11 (25%) .014†
Unrelated volunteer donor 24 (50%) 27 (61%)
Partially matched sibling
(haploidentical)
0 (0%) 3 (7%)
Unrelated cord blood 0 (0%) 3 (7%)
Conditioning regimen
Fully myeloablative 27 (56%) 16 (36%) .056
Reduced intensity 21 (44%) 28 (64%)
GVHD prophylaxis
CSA + MMF 47 (98%) 34 (77%)
Sirolimus +tacrolimus 1 (2%) 7 (16%)
Tacrolimus + MMF 0 (0%) 3 (7%)
AML indicates acute myelogenous leukemia; ALL, acute lymphoblastic
leukemia; CLL, chronic lumphocytic leukemia; CML, chronic myeloid
leukemia; CSA, cyclosporine; MDS, myelodysplastic syndrome; MMF,
mycophenolate mofetil; NHL, non-Hodgkin lymphoma.
*Median (interquartile range).
†HLA matched sibling versus alternative donor.maining 44 patients, 36 discontinued ciprofloxacin
because of fever and neutropenia requiring broader an-
tibiotic coverage, and 8 patients discontinued cipro-
floxacin at the time of neutrophil engraftment. The
median number of days of exposure to ciprofloxacin
in the NP cohort was 8 (interquartile range: 5.5-12).
All surviving patients in the PC cohort completed 60
days of ciproprofloxacin prophylaxis.
There were 11 cases of severe BKHC in the NP
group and 1 case in the PC group, occurring after
a median of 68.5 (range: 30-118) days after transplan-
tation. The long-recognized intrinsic relationship
between aGVHD and BKHC [7,11] was also verified
in the current series. Severe BKHC occurred in 9 of
38 (23.7%, 95% confidence interval [CI] 10.2%-
37.2%) patients with and in 3 of 54 (6.1%, 95% CI
0%-11.7%) patients without clinically significant
(grades B-D) aGVHD (P 5 .024). We also verified
an association between intensity of the conditioning
regimen and risk of severe BKHC. Overall, 11 of 43
(25.6%, 95% CI 12.5%-38.6%) patients receiving
a myeloablative conditioning regimen developed
severe BKHC compared to only 1 of 49 (2%, 95%
CI 0%-6%) patients receiving a reduced intensity
conditioning (P\ .001).
Using competing risk analysis (with death in ab-
sence of severe BKHC as a competing risk), the cumu-
lative incidence of severe BKHC was 20.9% (65.9%)
in NP and 2.6% (62.6%) in PC (Figure 1; P 5 .01).
By the same analysis, there was no statistically signifi-
cant difference between cumulative incidence of death
in absence of severe BKHC between NP and PC
(Figure 2; P5 .62). There was no difference in overall
survival (OS) between patients without and with severe
BKHC (P 5 .07). Estimated OS rates at day 100 were
82.8% (64.3%) and 83.3% (610.8%), whereas sur-
vival rates at 1 year were 66.1% (65.9%) and 40%
(614.6%).
In order to clarify whether the differences in inci-
dence of severe BKHC between the groups could be
linked to the exposure to ciprofloxacin and not only
to differences in prevalence of known risk factors for
BKHC, we performed Cox regression analysis for
the endpoint of incidence of severe BKHC. As dis-
played in Table 2, among the 5 variables integrating
the final model, only the use of a myeloablative regi-
men, the occurrence of grades B-D aGVHD, and the
lack of ciprofloxacin prophylaxis were independently
associated with higher risk of severe BKHC.Complications
There is concern that the prolonged use of antibi-
otic prophylaxis after transplantation may lead to in-
creased risk for infection by antibiotic-resistant
pathogens and Clostridium difficile diarrhea [19,20].
There were 28 episodes of bacteremia in NP (0.61
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Figure 1. Cumulative incidence of severe BK polyomavirus–associated
hemorrhagic cystitis (sBKHC) among patients receiving no prophylaxis
(NP) or prophylaxis with ciprofloxacin (PC).
Table 2. Multivariate Analysis for Incidence of Severe BKHC
Factor HR P
Sex (female) 0.35 (0.09-1.32) .12
Conditioning (myeloablative) 12.63 (1.46-109.0) .02
Mesna 4.99 (0.95-26.3) .58
Grades B-D aGVHD 6.87 (1.48-31.9) .01
Ciprofloxacin prophylaxis 0.03 (0.002-0.38) .007
HR indicates hazard ratio; aGVHD, acute graft-versus-host disease;
BKHC, BK virus-associated hemorrhagic cystitis.
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bacteremia in PC patients (0.19 episodes/100 days at
risk; P 5 .003). Only 1 of 10 episodes of Gram-
negative bacteremia in the NP group (Escherichia coli)
and 3 of 4 in the PC group (2 cases of Escherichia
coli and 1 case of Citrobacter freundii) were caused
by a fluoroquinolone-resistant pathogen (P 5 .04).
Table 3 display the pathogens implicated in episodes
of bacteremia for both groups.
There was no significant difference in occurrence
of episodes of Clostridium difficile diarrhea among the
groups with 3 episodes (0.07 episodes/100 days at
risk) in NP and 5 episodes (0.13 episodes/100 days at
risk) in PC (P 5 .48). All 8 episodes of Clostridium
difficile diarrhea were treated successfully with oral
metronidazole or vancomycin. Only 1 patient later0 500 1000 1500
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Figure 2. Cumulative incidence of death in absence of severe BK
polyomavirus–associated hemorrhagic cystitis (sBKHC) among patients
receiving no prophylaxis (NP) or prophylaxis with ciprofloxacin (CP).had a recurrence of the diarrhea and was successfully
retreated with metronidazole.DISCUSSION
Polyomavirus BK–associated hemorrhagic cystitis
can be distinguished from the hemorrhagic cystitis
caused by urothelial damaged from cytotoxic chemo-
therapy (particularly acrolein, a metabolite of cyclo-
phosphamide) on the basis of the latter onset, and
presence of high copy numbers of BK virus in the urine
and, less frequently, serum [1,2,6,12,13].
Even though BKHC and conditioning regimen-
induced HC have long been regarded as distinct
entities, they are likely interconnected. Urothelial
damage from the conditioning regimen triggers viral
replication and generation of an alloimmune reaction
[6,10,11,14], events known to be associated with
the development and sustainability of BKHC. In fact,
it is now recognized that the use of more intense
conditioning regimens, leading to more extensive
urothelial damage, is associated with higher incidence
of BKHC [3-5]. Leung et al. [14] have demonstrated
a correlation between the extent of BK virus urinary
shedding in the first 2 to 3 weeks after transplantation
and subsequent development of BKHC. Similarly,
a recent report including 209 patients successfully
correlated the presence of BK in the urine prior toTable 3. Episodes of Bacteremia
Pathogen
NP PC
n 5 28 n 5 7
Gram positives
Enterococcus spp 9 2
Staphylococcus aureus 3 1
Coagulase-negative Staphylococcus 4 0
Streptococcus mutans 1 0
Gram negatives
Acinetobacter baumannii 3 1
Klebsiella pneumoniae 3 0
Escherichia coli 0 2
Citrobacter freundii 1 1
Enterobacter spp 1 0
Burkholderia cepacia 1 0
Stenotrophomonas maltophilia 1 0
Others
Mycobacterium fortuitum 1 0
1180 Biol Blood Marrow Transplant 17:1176-1181, 2011A. N. Miller et al.initiation of the conditioning regimen with subsequent
development of symptomatic BKHC [3]. These find-
ings imply that strategies aiming at preventing the
development of BKHC would need to be instituted
early in the posttransplantation setting, particularly
during the first 60 days.
Currently, there is no established treatment for
BKHC. Its management consists mostly of transfusion
support, hydration, and in more severe cases, continu-
ous bladder irrigation or even cystectomy [12,21,22].
There have been many reports of the use of antiviral
agents, particularly cidofovir (intravenous and/or
intravesical), with the intent to improve or reverse
episodes of BKHC [4,23-26]. These reports,
however, are limited by small sample sizes and lack
of appropriate control groups.
Fluoroquinolones inhibit prokaryotic DNA gyrase
subunit A and are active in a plethora ofGram-negative
and Gram-positive infections. Fluoroquinolones also
inhibit in vitro the DNA gyrase produced as a conse-
quence of BK infection of mammalian cells, making
them promising agents for BKHC prophylaxis [14-
16]. Leung et al. [14] tested the impact of ciprofloxacin
treatment in a cohort of 68 patients undergoing alloge-
neicHSCT inHongKong. This study notedmarkedly
lower loads of BK urinary excretion in patients receiv-
ing ciprofloxacin for bacterial prophylaxis when
compared to patients receiving cephalosporins, trans-
lating into lower frequency of BKHC. Even though
this series provided strong rationale for ciprofloxacin
prophylaxis, it suffers from inconsistencies in the use
and duration of treatment with ciprofloxacin, small
sample size, and insufficient comparisons between
ciprofloxacin and nonciprofloxacin groups in terms of
patient and transplant-related characteristics.
UntilMarch, 2009, our programroutinely adminis-
tered ciprofloxacin as prophylaxis of bacterial infection
during the pre-engraftment phase. Given the strength
of the preliminary data, the importance of BKHC and
the relative ease in implementing this intervention, we
decide to extend ciprofloxacin prophylaxis until day
60. The current analysis suggests that this intervention
is both safe and effective, with a near 90% reduction in
the risk todevelop severeBKHC.Despite the inevitable
differences between groups, the impact of prophylaxis
remained significant even in multivariate analysis,
alongwith factors demonstrated inprior series tobe im-
plicated in BKHC, namely, GVHD and myeloablative
conditioning. To our knowledge, this is one of the first
comparative series, and the largest one, to confirm the
effectiveness of any pharmacological intervention in
preventing severe BKHC after allogeneic HSCT. Sim-
ilar analysis in cohorts of patients undergoing renal
transplantation have shown that prolonged exposure
to fluoroquinolones are associated with reduced risk
of BK viremia and BK nephropathy [27]. Even though
the present study addresses the effect of ciprofloxacinin BKHC, its proposed mechanism of action is shared
by other fluroquinolones, such as levofloxacin, and is
likely class-specific instead of drug-specific. In fact,
there is preliminary evidence that levofloxacin also
can be effective in preventing BK virus–associated
complications after kidney transplantation [27].
It is important to emphasize that ciprofloxacin pro-
phylaxis was in general safe, with none of the patients
in the PC cohort discontinuing therapy prior to day 60
after transplantation. Extended use of ciprofloxacin did
not seem to increase the incidence ofC. difficile diarrhea.
Interestingly, there was a marked reduction in the risk
of bacteremia during the first 100 days after transplanta-
tion in the PCgroup.However, bacteremias developing
in the setting of ciprofloxacin prophylaxis were more
likely to be caused by a fluoroquinolone-resistant
pathogen. These observations demand caution, as they
are preliminary and retrospective. Further studies are
needed to properly assess the safety of extended prophy-
laxis with ciprofloxacin after HSCT.
The main limitation of this report is its retrospec-
tive nature, only partially overcome by the multivariate
analysis. Even though unaccounted differences in
supportive care between cohorts may have affected the
outcome, this is unlikely to be the case, because all the
transplants in both cohorts occurred during a relatively
short period of time (56 months) with no other interim
substantial change in supportive care practices.
Another caveat is the possibility that the apparent
reduction in incidence of severe BKHC may be in
fact a result of regression to the mean and not truly
an impact of the institution of ciprofloxacin prophy-
laxis [28]. In this scenario, an unusual, ‘‘by chance,’’
high incidence of severe BKHC during a determined
period (covered by the NP cohort) would have trig-
gered the institution of ciprofloxacin prophylaxis.
The subsequent reduction in severe BKHC would be
an expected regression toward average rates instead
of a true effect of the intervention. Although possible,
this hypothesis is unlikely, considering the marked dif-
ferences observed between PC and NP and the rate of
severe BKHC seen in the NP group are comparable to
those reported in the literature [1-6].
In summary, ciprofloxacin prophylaxis appears safe
and effective in reducing the incidence of severe BKHC
after allogeneic HSCT, with potential concomitant re-
duction in the risk of bacteremias. This finding requires
confirmation with a prospective randomized trial. Such
trial may focus on high-risk patients and should ideally
be accompanied by prospective monitoring of BK virus
urinary shedding and viremia.ACKNOWLEDGMENTS
Financial disclosure: The authors have nothing to
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